Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children With Average-Risk Medulloblastoma and Reduced Therapy in Children With Medulloblastoma With Low-Risk Features

NCT05382338 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT05382338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05382338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children With Average-Risk Medulloblastoma and Reduced Therapy in Children With Medulloblastoma With Low-Risk Features
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Recruiting
Start date
February 20, 2023
Completion date
December 31, 2029
Enrollment
225 (estimated)
Sites
111

Conditions

As the registry lists them; a condition with its own page is linked.

childhood medulloblastoma